New research from The University of Texas at Arlington shows that differences in state welfare policies are linked to rising arthritis-related joint pain across much of the U.S.

Dr. Jack Cush reviews the news, FDA approvals, and journal articles. In this episode: HMGCR Abs, FDA approvals and Cush eats crow.

The NY Times has addressed the problem of osteoporosis in men noting a need for increased awareness and screening. Takeaways:

Analysis of a German psoriatic arthritis (PsA) patients registry demonstrates sex-specific differences regarding clinical manifestation and treatment outcomes, especially with regard to drug discontinuations.

A Veterans Affairs (VA) Health Systems study of older male veterans found benefits of a remote model of screening that significantly improved osteoporosis screening, treatment, and adherence compared with usual care, with high patient and clinician acceptance.

A phase IV trial from Spain demonstrates that optimization of therapy by lessening biological DMARDs in rheumatoid arthritis (RA) may be feasible, with a low risk of flare.

Dr. Jack Cush reviews the news, journal reports and important associations in rheumatology from the past week on RheumNow.com.

People with rheumatoid arthritis (RA) who experienced disease flares often showed changes in heart rate and physical activity captured by popular wearable devices 4 weeks before they became clinically apparent, a small study indicated.

An exercise and diet intervention study showed that while exercise improved hip pain, adding a weight loss diet to exercise did not change hip pain but improve most secondary outcomes.

Dr. Jack Cush reviews the news and journal articles from RheumNow.com. Pool therapy, Fibrosis, NSIE's and what's best for knee OA. 

Dr. Jack Cush reviews the news and journal reports from this week on RheumNow.com. Today we cover GLP-1 agonists, acupuncture, what JAKs won’t do & an FDA Pink Slip. 

Dr. Jack Cush reviews the news and journal reports from RheumNow. This week - unemployment, diagnosing Sjogren's and a lot of ILD.

On behalf of the American College of Rheumatology (ACR), we express deep concern over recent developments at the Centers for Disease Control and Prevention (CDC) that appear to undermine the agency’s longstanding commitment to science-based public health policy.